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Germ	cell	cancer	 is	the	most	frequent	malignant	
tumor	type	in	young	men,	and	its	incidence	has	con-
tinuously	been	increasing	[1].	Fortunately,	during	the	
last	25	years	it	has	become	the	“model”	of	a	curable	
neoplasm.	The	major	factor	for	the	high	cure	rate	is	
the	high	level	of	sensitivity	of	germ	cell	cancer	cells	
to	a	variety	of	chemotherapeutic	agents,	in	particular	
to	 cisplatin.	 Following	orchiectomy,	which	 should	
regularly	be	performed	prior	to	any	further	treatment,	
today,	patients	suffering	from	a	seminoma	(stage	≥	IIC)	
or	non-seminoma	(stage	≥	IIA)	should	receive	com-
bined	chemotherapy	comprising	cisplatin,	etoposide,	
and	bleomycin	(BEP-regimen)	[1].	For	patients	with	
good	and	intermediate/poor	prognosis,	according	to	
IGCCCG	criteria	[2],	standard	treatment	is	three	and	
four	cycles	of	BEP,	 respectively	 [2–4].	 In	addition,	
in	patients	with	non-seminoma	who	show	 residual	
masses	of	≥	1	cm	and	normalisation	of	 tumor	mar-
kers	after	systemic	therapy	the	residual	masses	have	
to	be	resected	[5–7].	Histopathological	examination	
of	RPLND	sections	in	case	of	residual	retroperitoneal	
disease	after	 first-line	chemotherapy	have	 revealed	
necrosis,	mature	teratoma	and	active	vital	cancer	in	
about	50%,	35%,	and	15%	of	patients,	respectively	[1,	
8].	However,	we	still	lack	reliable	markers	predicting	
the	character	of	the	residual	masses	prior	to	surgery,	
even	though	size,	the	histology	of	the	testicular	tumour	
and,	 if	 applicable,	 the	expression	of	serum	 tumour	
markers	do	have	indicating	potential.
Multidrug	resistance	(MDR)	is	a	phenomenon	that	
renders	cells	 resistant	 to	chemotherapeutic	agents	
in	many	cancer	patients.	One	of	 the	mechanisms	
responsible	for	this	pleiotropic	effect	is	reduced	drug	
accumulation	inside	the	cells,	due	to	the	activity	of	a	
170	kDa	transmembrane	protein,	MDR1	(P-glycopro-
tein,	P-gp,	,	P-170,	or	mdr1	gene	product)	[9,	10].	Eid	
et	al.	[11]	were	able	to	show	that	MDR1	is	frequently	
overexpressed	 in	germ	cell	 testicular	 tumors	of	ad-
vanced	stage		and	aggressive	phenotype	[12].
The	aim	of	this	study	was	to	evaluate	the	signifi-
cance	of	MDR1	expression	to	predict	necrosis/fibrosis,	
teratoma	or	viable	tumor	in	residual	retroperitoneal	tu-
mor	masses	after	systemic	chemotherapy.	Moreover,	
we	investigated	whether	the	MDR1	level	pre/post-che-
motherapy	was	associated	with	a	specific	histological	
tumour	subtype	and/or	influenced	by	prior	cytotoxic	
treatment.
Materials and Methods
Patients and histology.	All	patients	 (n	=	77)	 in-
cluded	in	this	retrospective	study	had	been	treated	at	
the	Philipps-University	Medical	School,	Marburg	(n	=	64)	
and	the	Bundeswehrzentralkrankenhaus,	Koblenz,	(n	=	
13)	between	1987	and	2002.	Study	was	agreed	with	local	
ethical	committee	and	informed	consents	from	patients	
were	received.	Testicular	specimens	were	obtained	from	
72	patients	who	had	undergone	orchiectomy	for	testis	
cancer.	The	tumors’	histology	was	classified	due	to	the	
World	Health	Organisation	(WHO)	[13].	Median	age	at	
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surgery	was	29	years	(range,	14–67).	The	majority	of	
patients	suffered	 from	retroperitoneal	metastases	at	
diagnosis:	clinical	stage	I,	II	and	III	were	diagnosed	in	5,	
37,	and	35	patients,	respectively.	Following	initial	orchi-
ectomy,	all	patients	received	platin	based	chemotherapy	
including	combinations	with	bleomycin	(B),	cisplatin	(C),	
etoposide	(E),	ifosfamide	(I),	and/or	carboplatin.	Subse-
quently	retroperitoneal	lymph	node	dissection	(RPLND)	
was	performed	in	all	patients;	histological	specimens	
were	obtained	and	classified	 into	complete	necrosis,	
mature	 teratoma,	and	active	viable	 tumor.	Moreover,	
tissue	samples	 to	evaluate	MDR1	expression	were	
available	 from	primary	 testicular	 tumors	and	RPLND	
specimens	from	47	and	73	patients,	respectively.
Antibodies.	The	monoclonal	mouse	IgG2b	antibody	
Mdr	(G-1):	sc-13131	(Santa	Cruz	Biotechnology,	Santa	
Cruz,	CA,	USA),	diluted	1	:	250	and	1	:	500,	was	used	
for	the	detection	of	MDR1	expression	[14].	The	optimal	
dilution	for	immunostaining	was	obtained	using	testicu-
lar	tumor-tissue	as	control;	the	optimal	titer	was	defined	
as	the	dilution	that	gave	clearly	identifiable	membrane	
or	granular	cytoplasmatic	staining.	Normal	 testicular	
tissue	served	as	negative	control.
Immunohistochemistry.	 Immunohistochemical	
staining	was	performed	with	the	3,3’-diaminobenzidine	
(DAB)	chromogen	—	detection	method	(DAKO	Cytoma-
tion,	Hamburg,	Germany)	employing	an	enzyme	linked	
antibody	 technique.	Briefly,	paraffin	serial	 sections	
were	prepared	 in	xylol	and	hydrated	 in	ethanol.	The	
peroxidase	was	 inactivated	with	phosphate-buffered	
saline	(PBS)	and	3%	H2O2.	Subsequently,	the	sections	
were	dampened	with	target	retrieval	solution	(pH	6.1;	
TAKO	Cytomation,	Hamburg,	Germany)	and	incubated	
in	water	vapour	at	94	°C	for	30	min.	After	rehydration	with	
phosphate-buffered	saline	(PBS),	the	sections	were	in-
cubated	in	PBS	containing	2%	skim	mild	powder	solution	
(Fluka	BioChemika,	Buchs,	Switzerland).	Subsequently,	
these	sections	were	exposed	to	the	primary	antibody	
sc-13131	for	60	min	followed	by	an	incubation	with	anti-
mouse	EnVision®	 labelled	polymer	 immunoglobulin	
(DAKO	Cytomation,	Hamburg,	Germany)	 for	30	min	
at	20	 °C.	Each	step	was	followed	by	washing	 in	PBS.	
Finally,	they	were	immersed	in	DAB	(Liquid	DAB+	sub-
strate	solution,	DAKO,	Hamburg,	Germany)	for	15	min	
to	visualise	the	reaction	products.	After	washing	in	aqua	
dest,	specimens	were	counterstained	with	Mayer’s	hae-
malaun	solution	(Merck,	Darmstadt,	Germany).
Scoring of immunostaining results.		The	evalua-
tion	of	 immunostaining	results	was	scored	by	two	 in-
vestigators	without	knowledge	of	the	clinical	data	of	the	
patients.	Sections	were	scored	as	follows:	–,	no	staining;	
+,	positive	staining	(weak/moderate);	++,	strong	staining	
in	most	tumor	cells.	
Statistics.	Data	analysis	was	performed	using	
the	SPSS	statistical	 software	package	 (SPSS,	 Inc.,	
Chicago,	USA).	Relations	between	clinicopathological	
characteristics	and	staining	of	MDR1	were	determined	
using	χ2	analysis	and	the	Fisher-exact-test	with	p	<	0.05	
considered	significant.	MDR1	expressions	pre-	and	post-	
chemotherapy	were	compared	with	the	Wilcoxon	test.	
results
Histology of the testicular tumor and residual 
retroperitoneal tumor mass after chemotherapy. 
The	histological	subtype	of	the	primary	testicular	tu-
mor	was	available	from	72	patients;	17	(23.6%)	and	
55	 (76.4%)	suffered	 from	a	seminoma	and	NSGCT	
(nonseminomatous	germ	cell	 tumor),	 respectively.	
Out	of	those	with	NSGCT,	30	patients	presented	with	
primary	tumor	containing	teratoma.	After	orchiectomy	
and	chemotherapy	with	various	regimens	(BEP,	PEI,	
Carboplatin)	and	dosage	 (2–6	cycles),	RPLND	was	
performed	 in	all	77	patients,	and	the	residual	 retro-
peritoneal	 tumor	masses	were	examined	histologi-
cally.	Entirely	necrotic	tumor	tissue,	mature	teratoma,	
and	active	 viable	 tumor	were	 found	 in	44	 (57.1%),	
18	(23.4%),	and	15	(19.5%)	patients,	respectively.
Moreover,	we	examined	whether	 the	 tumor	sub-
type	 of	 the	 primary	 testicular	 tumor	 predicts	 the	
histological	findings	after	RPLND.	Out	of	17	patients	
with	seminoma,	only	2	(11.8%)	and	1	(5.9%)	patients	
presented	with	pure	teratoma	and	viable	cancer	in	the	
residual	 retroperitoneal	 tumor	masses.	 In	contrast,	
in	15	 (27.3%)	and	14	 (25.5%)	patients	with	NSGCT	
(n	=	55),	teratoma	and	viable	tumor	tissue	were	found	
in	RPLND	sections,	respectively	(p	=	0.048;	Fisher’s	
exact	 test;	 the	Table).	 Looking	at	 the	 subgroup	of	
	NSGCT	patients	with	 teratoma-constituents	 in	 their	
primary	 testicular	 tumor	tissue	(n	=	30)	 in	compari-
son	to	all	patients	with	teratoma-free	primary	tumors	
(n	=	42),	 the	correlation	was	even	more	significant:	
teratoma	and	viable	germ	cell	tumor	in	RPLND	sec-
tions	were	found	in	40%	versus	11.9%	and	30%	versus	
14.3%	of	patients	(p	=	0.001;	Fisher’s	exact	test).	All	
results	are	summarized	in	the	Table.
Table. Histopathology and MDR1 expression in primary testicular tumours 
and the respective retroperitoneal RPLND sections after chemotherapy
Primary tumor
RPLND histology
Viable 
tumor
Mature 
teratoma Necrosis Total
Histology Testicular Tumor
Seminoma (%) 1 (5.9%) 2 (11.8%) 14 (82.4%) 17 (100%)
NSGCT (%) 14 (25.5%) 15 (27.3%) 26 (47.3%) 55 (100%)
Total (%) 15 (20.8%) 17 (23.6%) 40 (55.6%) 72 (100%)
Teratoma-free (%) 6 (14.3%) 5 (11.9%) 31 (73.8%) 42 (100%)
Teratoma-components (%) 9 (30%) 12 (40%) 9 (30%) 30 (100%)
Total (%) 15 (20.8%) 17 (23.6%) 40 (55.6%) 72 (100%)
MDR1 Expression Testicular Tumor
Negative (%) 3 (12.5%) 2 (8.3%) 19 (79.2%) 24 (100%)
Low/moderate (%) 2 (40%) 2 (40%) 1 (20%) 5 (100%)
High (%) 5 (27.8%) 8 (44.4%) 5 (27.8%) 18 (100%)
Total (%) 10 (21.3%) 12 (25.5%) 25 (53.2%) 47 (100%)
In	 total,	 the	 histological	 differentiation	 of	 the	
primary	 testicular	 tumor	 (NSGCT/seminoma	and	
teratoma/non-teratoma)	allowed	prediction	of	 the	
composition	of	residual	retroperitoneal	tumor	masses	
following	chemotherapy.
MDR1 expression in the primary testicular 
tumor and the residual retroperitoneal tumor 
mass after chemotherapy. MDR1	expression	was	
determined	by	 immunohistochemistry	 in	47	primary	
tumor	 samples	 and	77	RPLND	sections	 following	
chemotherapy.	Perfoming	semiquatitative	analysis	24	
(51.1%)	patients	presented	with	testicular	germ	cell	
tumors	lacking	MDR1	protein	whereas	weak/modera-
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te	and	strong	staining	were	 found	 in	5	 (10.6%)	and	
18	 (38.3%)	patients,	 respectively	 (the	 Table).	No	
seminomatous	tumor	expressed	MDR1.	In	contrast,	
5	(16.7)	and	18	(60.0%)	out	of	30	NSGCT	expressed	
weak/moderate	and	high	levels	of	MDR1	protein,	re-
spectively	(p	<	0.001,	Fisher’s	exact	test).	Moreover,	
in	testicular	tumors	containing	teratoma-constituents	
MDR1	was	detected	in	a	significantly	higher	frequency	
(15/18,	83.3%)	compared	 to	 teratoma-free	 tumors	
(8/29,	27.6%;	p	<	0.001,	Fisher’s	exact	test).	
Looking	at	the	sections	of	residual	retroperitoneal	
masses	obtained	during	RPLND	after	chemotherapy,	
weak/moderate	and	high	MDR1	protein	 levels	were	
identified	in	18	(24.7%)	and	8	(11%)	out	of	73	evaluable	
patients,	respectively.	Regarding	the	MDR1	expression	
level	there	was	no	difference	between	RPLND	sections	
containing	viable	 tumor	 (12/14)	or	mature	 teratoma	
(14/15;	p	=	0.75,	Fisher’s	exact	 test),	neither	within	
the	expression	level	of	each	group	(p	>	0.15;	binominal	
analysis).	No	specific	MDR1	staining	was	detected	in	
necrotic	tissue	samples	(n	=	47).
Evaluating	whether	the	MDR1	expression	level	de-
tected	in	the	primary	testicular	germ	cell	tumor	might	
predict	 the	histological	 outcome	after	RPLND,	we	
were	able	to	reveal	a	significant	correlation.	In	patients	
whose	 testicular	 tumour	stained	positive	 for	MDR1	
protein	expression	(n	=	23)	the	likelihood	of	persisting	
residual	retroperitoneal	disease	(mature	teratoma	or	
active	viable	 tumor)	was	significantly	higher	 than	 in	
patients	with	MDR1-negative	primary	tumors	(n	=	24;	
73.9%	vs	20.8%;	p	=	0.003,	Fisher’s	exact	test).	
However,	MDR1	expression	was	significantly	as-
sociated	with	the	tumors	histological	characteristics	
(vide	supra).	Therefore,	we	evaluated	whether	MDR1	
might	serve	as	an	independent	marker	of	residual	ret-
roperitoneal	tumor	after	chemotherapy.	We	found	that	
the	MDR1	expression	alone	did	not	reach	statistical	
significance	as	an	independent	marker	for	residual	vital	
tumor	(p	≥	0.16,	Fisher’s	exact	test)	as	its	expression	
was	highly	associated	with	the	histological	subtype	of	
the	primary	testicular	tumor	(NSGCT/seminoma	and	
teratoma-containing/free	disease).	
Interesting,	looking	at	those	47	patients	whose	tes-
ticular	and	retroperitoneal	tumor	tissue	was	available	
for	MDR1	staining,	we	were	able	to	show	that	the	mean	
MDR1	expression	level	was	rather	lower	in	the	retro-
peritoneal	lymph	node	tissue	following	chemotherapy	
compared	to	the	primary	testicular	tumor	(increased,	
stable,	and	decreased	 in	8.5%,	59.6%,	and	31.9%,	
respectively;	p	=	0.018,	Wilcoxon	test).	
discussion
The	multidrug	 resistance	gene	product	MDR1	
(P-glycoprotein)	 belongs	 to	 the	 super	 family	 of	
ATP-binding	cassette	(ABC)	transporters	whose	func-
tions	include	the	efflux	of	ions,	nutrients,	lipids,	amino	
acids,	peptides,	proteins	and	—	in	particular	—	cytotoxic	
drugs	[15–17].	 In	many	human	cancers,	 the	 level	of	
MDR1-expression	 is	an	 important	 independent	pro-
gnostic	factor	that	determines	response	to	combination	
chemotherapy	[18,	19].	Recent	clinical	trials	in	haema-
tological	and	solid	malignancies	have	shown	promise	
for	a	prolonged	remission	and	improved	overall	survival	
by	combining	MDR1	inhibitors	with	chemotherapy	[18,	
20].	Germ	cell	 testicular	 tumors	 in	general	are	very	
sensitive	to	systemic	anti-cancer	treatment.	However,	
especially	patients	with	stage	≥	 IIC	nonseminoma,	
particularly	with	teratoma-components	in	their	primary	
testicular	tumor,	frequently	present	with	residual	retro-
peritoneal	disease	following	chemotherapy	which	has	
to	be	dissected	after	 initial	chemotherapy	 to	ensure	
therapeutic	success	[1,	4].	Therefore,	this	study	was	
performed	to	investigate	whether	MDR1	expression	in	
testicular	tumor	tissue	could	serve	as	an	independent	
marker	for	residual	vital	tumor	growth,	and	potentially	
chemoresistance.	Moreover,	we	intended	to	prove	an	
association	between	MDR1	expression	and	different	
malignant	tumor	subtypes.
In	our	patient	 cohort	 high	expression	of	MDR1	
was	particularly	observed	in	NSGCT	containing	tera-
toma-components	whereas	pure	seminoma	did	not	
express	any	detectable	MDR1	protein.	This	is	in	well	
accordance	with	earlier	studies	published	by	Katagiri,	
Eid	et	al.	[11,	12,	21].	The	latter	group	identified	MDR1	
protein	expression	in	two	(8%)	of	25	seminomatous	
and	23	(46%)	out	of	50	non-seminomatous	testicular	
tumors.	Unlike	Katagiri	et	al.	 [21],	 they	 further	 indi-
cated	that	there	might	exist	a	positive	correlation	be-
tween	MDR1	expression	and	tumor	stage	[11]	as	well	
as	a	progressive	malignant	phenotype	[12].	
Evaluating	the	potential	predictive	value	of	MDR1	
expression	 in	 testicular	 tumor	 tissue	 for	active	ma-
lignant	 residues	after	chemotherapy	we	were	able	
to	show	that	at	least	using	univariate	analysis	MDR1	
expression	was	significantly	correlated	with	positive	
RPLND	sections:	 for	patients	with	MDR1	negative	
and	positive	primary	cancer	5/24	(20.8%)	and	17/23	
(73.9%)	RPLND	specimens	 tested	positive	 for	 vital	
residual	disease,	respectively.	However,	in	our	study	
the	MDR1	expression	level	was	significantly	associated	
with	the	non-seminomatous	tumor	subtype.	Therefore,	
we	evaluated	whether	MDR1	might	also	have	the	ca-
pacity	to	serve	as	a	tumor-type	independent	marker	for	
residual	retroperitoneal	disease	after	chemotherapy.	
Conversely,	we	revealed	that	its	expression	alone	failed	
to	 reach	statistical	 significance	as	an	 independent	
marker	for	residual	vital	tumor,	even	though	there	was	
a	positive	statistical	trend.
A	large	number	of	authors	 investigate	MDR1	ex-
pression	in	hematologic	(AML,	CLL,	multiple	myeloma)	
as	well	as	solid	malignancies	including	breast	cancer,	
ovarian	cancer,	 cervical	 cancer,	CNS	cancer,	 and	
osteosarcoma.	They	 indicated	 that	MDR1	expres-
sion	 levels	are	 frequently	up-regulated	by	systemic	
chemotherapy	as	compared	to	those	prior	to	therapy	
(for	 review	see	[20,	22]).	However,	our	 results	sug-
gest	a	different	regulation	in	germ	cell	cancer:	Out	of	
47	patients	whose	testicular	and	retroperitoneal	tissue	
were	available	for	MDR1	staining,	we	found	out	that	
MDR1	was	upregulated	by	platinum	based	treatment	
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in	a	minority	of	patients	(4/47,	8.5%),	only.	In	contrast,	
no	significant	change	and	a	decrease	in	MDR1	expres-
sion	were	seen	in	28/47	(59.6%)	and	15/47	(31.9%)	
samples.	However,	unlike	most	of	those	tumors	with	
upregulated	MDR1	 levels	 after	 chemotherapy	 the	
majority	of	testicular	germ	cell	tumors	is	highly	che-
mosensitive	which	might	account	 for	 the	dissimilar	
regulation	revealed	here.	
Taken	 together,	MDR1	was	 frequently,	 at	 times	
highly	expressed	in	NSGCT,	only.	Both,	MDR1	expres-
sion	and	the	non-seminomatous	histological	subtype	
correlated	with	viable	residual	disease	found	in	retro-
peritoneal	 lymph	nodes	after	chemotherapy.	On	the	
other	hand,	in	our	rather	small	cohort	of	patients	MDR1	
expression	alone	failed	to	reach	statistical	significance	
as	a	histology-independent	marker	 for	residual	vital	
tumor.	Therefore,	up	 to	now	 routine	MDR1	staining	
of	testicular	germ	cell	cancer	samples	should	not	be	
performed	in	clinical	practice.	However,	as	there	was	a	
statistical	trend	towards	significance,	our	study	should	
and	will	be	continued	with	a	larger	number	of	patients	
suffering	from	metastatic	NSGCT,	only,	as	it	appears	
that	MDR1	expression	could	have	prognostic	value	in	
this	subgroup	of	testicular	germ	cell	cancer	patients.	
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клиническая значимость экспрессии Mdr1 
при герминативном раке яичка
Белок� 1 ��о�е���е��о�� лек������е��о�� ���о�����о��� (MDR1, P-gp, p-170) �� ��о �е��������� �л�к�о��о�е��, ���к���о��-            
��ющ��� к��к� ��е��оз��������� ���о�. ��� ��зл������ �о����� о����оле�� е�о �к����е����� ����з��� � ���о�����о���ю о����ол� к�            
��зл����� ���о�����к���, ��о �о�е� ���� ���ол�зо���о дл�� ���о�� ���� �е�����. Цель работы — ���ледо����е ��о��о���-
�е�к�о�� з�����о��� �к����е���� MDR1 � �к���� �е�����о�� о����ол� дл�� о�е�к�� �оз�о��о��� ��з������ �ек��оз� �л� �о�����е����             
������ к�ле�ок� � о����о��о�� �к���� о����ол� �о�ле ����е�е���� ����е��о�� �����о�е����� �� �озд���� ���д����� �е������������ 
о����оле�� ����к��. Материалы и методы: ��о���л�з��о���� ����о���оло���е�к��е �����к��е�����к�� �е�����о�� �е���к��л����о��     
о����ол� � о���з�о�, �ол��е����� ��� ���е�е��� �е��о�е���о�е�л����� л�������е�к���� �зло� (RPLND) �о�ле �����о�е����� �    
72 � 77 �ол����� �оо��е����е��о. �к����е���ю MDR1 о��едел��л� �����о����о������е�к��� �е�одо� � 47 о���з���� �е�����о��             
о����ол� � �оо��е�����ющ��� 73 ��ез��� RPLND.   Результаты: �о�ле �����о�е����� � �о�лед�юще�� RPLND ���ледо����е о���-      
�о����� о����оле���� �к���е�� �ок��з�ло, ��о з�ел��� �е���о�� � ��з�е��о�о���е о����оле��е к�ле�к�� �����л��ю� ��е���ще���е��о         
� �ол�����, � к�о�о���� �е ��л� о������е�� �е���о�� (NSGCT;  p = 0,048), о�о�е��о � ��к�о����, � к�о�о���� ��л� �е���о�� (       p = 
0,001). Более �о�о, д����е од�о��к��о��о�о ���л�з� �ок��з�л�, ��о �к����е����� MDR1 � �к���� �е�����о�� �е���к��л����о�� о��-             
��ол� �о�е� �л����� ��о��о����е�к��� ��к��о�о� �о�����е���� ������ о����оле���� к�ле�ок� � ��ез��� RPLND (            p = 0,003). �д��к�о 
����е�е��е ��л�����к��о��о�о ���л�з�, � �о� ���ле � ��е�о� ����оло���е�к�о�о �од���� о����ол�, �ок��з�ло, ��о �к����е�����    
MDR1 �е ��ее� ���о��о���ел��о�� ��о��о����е�к�о�� з�����о��� дл�� �����ле���� ������ о����о����� о����оле���� к�ле�ок� (p ≥             
0,16). Выводы: ���д� �е�ол��о�� ���о�к�� �ол����� �е �����ле�о ���������е�к�� з�����о�� к�о��ел����� �е�д� �к����е���е�� MDR1            
� �е�����о�� о����ол� ����к�� � ��л���е� �к�������� �ез�д��л����� о���о� �о���е���� � �е��о�е���о�е�л��о� ��о��������е. �� �о   
�е ��е���, ��������� �����ле���ю �е�де���ю, �к����е���ю MDR1, � к���е���е �оз�о��о�о ��о��о����е�к�о�о ���к�е��, ��ее�       
����л ���ледо���� ��е��о � �ол����� � �е��������е�к���� о����ол����, �е ���л��ющ������ �е���о�о��.
Ключевые слова: ����к�о, о����ол�, �е���о��, �е���о��, P-gp, p170, ���е�е��е �е��о�е���о�е�л����� л�������е�к���� �зло�.         
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